Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board

NEEDHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Carl H. June, M.D., to Candel’s Research Advisory Board (RAB). Dr. June, an internationally recognized expert in cancer immunotherapy, and a pioneer in developing the first U.S. Food and Drug Administration (FDA)-approved CAR-T cell therapy, will bring Candel his deep expertise, as Candel continues to advance its lead viral immunotherapy candidate CAN-2409 across multiple solid tumor indications and CAN-3110 for recurrent high-grade glioma.

“I’m pleased to join Candel’s Research Advisory Board at such a pivotal time for the Company,” said Dr. June. “Candel’s innovative approach to viral immunotherapy aligns with my passion for harnessing the power of the immune system to fight cancer. I look forward to contributing to the advancement of these promising therapies that have the potential to help patients across multiple cancer types.”